BBB opening by low pulsed electric fields, depicted by delayed-contrast MRI, enables efficient delivery of therapeutic doxorubicin doses into mice brains

[1]  Christopher G. Rylander,et al.  Advancements in drug delivery methods for the treatment of brain disease , 2022, Frontiers in Veterinary Science.

[2]  J. Robertson,et al.  High-Frequency Irreversible Electroporation (H-FIRE) Induced Blood–Brain Barrier Disruption Is Mediated by Cytoskeletal Remodeling and Changes in Tight Junction Protein Regulation , 2022, Biomedicines.

[3]  W. Löscher,et al.  Is P-Glycoprotein Functionally Expressed in the Limiting Membrane of Endolysosomes? A Biochemical and Ultrastructural Study in the Rat Liver , 2022, Cells.

[4]  G. Hutter,et al.  Targeting immunoliposomes to EGFR-positive glioblastoma , 2022, ESMO open.

[5]  C. Arena,et al.  An Investigation for Large Volume, Focal Blood-Brain Barrier Disruption with High-Frequency Pulsed Electric Fields , 2021, Pharmaceuticals.

[6]  D. Gandhi,et al.  Localized blood–brain barrier opening in infiltrating gliomas with MRI-guided acoustic emissions–controlled focused ultrasound , 2021, Proceedings of the National Academy of Sciences.

[7]  Jia Ouyang,et al.  Doxorubicin Delivered via ApoE-Directed Reduction-Sensitive Polymersomes Potently Inhibit Orthotopic Human Glioblastoma Xenografts in Nude Mice , 2021, International journal of nanomedicine.

[8]  Liliana Aranda-Lara,et al.  Evaluation of doxorubicin-induced early multi-organ toxicity in male CD1 mice by biodistribution of 18F-FDG and 67Ga-citrate. Pilot study , 2021, Toxicology mechanisms and methods.

[9]  Liqing Chen,et al.  Efficient antiglioblastoma therapy in mice through doxorubicin-loaded nanomicelles modified using a novel brain-targeted RVG-15 peptide , 2021, Journal of drug targeting.

[10]  Antiño R. Allen,et al.  Cognitive impairment resulting from treatment with docetaxel, doxorubicin, and cyclophosphamide , 2021, Brain Research.

[11]  P. Wipf,et al.  Endothelial Iron Homeostasis Regulates Blood-Brain Barrier Integrity via the HIF2α—Ve-Cadherin Pathway , 2021, Pharmaceutics.

[12]  J. Kuo,et al.  Neuronavigation-guided focused ultrasound for transcranial blood-brain barrier opening and immunostimulation in brain tumors , 2021, Science Advances.

[13]  Y. Mardor,et al.  Non-Invasive Low Pulsed Electrical Fields for Inducing BBB Disruption in Mice—Feasibility Demonstration , 2021, Pharmaceutics.

[14]  B. Vollmar,et al.  Analysis of Animal Well-Being When Supplementing Drinking Water with Tramadol or Metamizole during Chronic Pancreatitis , 2020, Animals.

[15]  F. Gosselet,et al.  Caspase-1 has a critical role in blood-brain barrier injury and its inhibition contributes to multifaceted repair , 2020, Journal of neuroinflammation.

[16]  E. Leuthardt,et al.  Therapeutic enhancement of blood–brain and blood–tumor barriers permeability by laser interstitial thermal therapy , 2020, Neuro-oncology advances.

[17]  N. McDannold,et al.  Secondary effects on brain physiology caused by focused ultrasound-mediated disruption of the blood-brain barrier. , 2020, Journal of controlled release : official journal of the Controlled Release Society.

[18]  R. Davalos,et al.  Cytoskeletal Disruption after Electroporation and Its Significance to Pulsed Electric Field Therapies , 2020, Cancers.

[19]  Y. Mardor,et al.  The effects of point-source electroporation on the blood-brain barrier and brain vasculature in rats: An MRI and histology study. , 2020, Bioelectrochemistry.

[20]  Y. Mardor,et al.  The application of point source electroporation and chemotherapy for the treatment of glioma: a randomized controlled rat study , 2020, Scientific Reports.

[21]  Eun-hee Lee,et al.  An advanced focused ultrasound protocol improves the blood-brain barrier permeability and doxorubicin delivery into the rat brain. , 2019, Journal of controlled release : official journal of the Controlled Release Society.

[22]  David Borsook,et al.  The neurovascular response is attenuated by focused ultrasound-mediated disruption of the blood-brain barrier , 2019, NeuroImage.

[23]  Costas D. Arvanitis,et al.  The blood–brain barrier and blood–tumour barrier in brain tumours and metastases , 2019, Nature Reviews Cancer.

[24]  Y. Mardor,et al.  Transient blood–brain barrier disruption is induced by low pulsed electrical fields in vitro: an analysis of permeability and trans-endothelial electric resistivity , 2019, Drug delivery.

[25]  Eduardo L. Latouche,et al.  High-Frequency Irreversible Electroporation for Intracranial Meningioma: A Feasibility Study in a Spontaneous Canine Tumor Model , 2018, Technology in cancer research & treatment.

[26]  J. Frank,et al.  Reply to Silburt et al.: Concerning sterile inflammation following focused ultrasound and microbubbles in the brain , 2017, Proceedings of the National Academy of Sciences of the United States of America.

[27]  N. McDannold,et al.  Evaluation of permeability, doxorubicin delivery, and drug retention in a rat brain tumor model after ultrasound‐induced blood‐tumor barrier disruption , 2017, Journal of controlled release : official journal of the Controlled Release Society.

[28]  G. Pazour,et al.  Ror2 signaling regulates Golgi structure and transport through IFT20 for tumor invasiveness , 2017, Scientific Reports.

[29]  Damijan Miklavcic,et al.  A statistical model describing combined irreversible electroporation and electroporation-induced blood-brain barrier disruption , 2016, Radiology and oncology.

[30]  D. Miklavčič,et al.  A statistical model describing combined irreversible electroporation and electroporation-induced blood-brain barrier disruption. , 2016, Radiology and Oncology.

[31]  H. Ovadia,et al.  Modulation of Hyperosmotic and Immune-Induced Disruption of the Blood-Brain Barrier by the Nitric Oxide System , 2015, Neuroimmunomodulation.

[32]  Amy C. Dwyer,et al.  Models and methods for analyzing DCE-MRI: a review. , 2014, Medical physics.

[33]  Yael Mardor,et al.  Dynamic effects of point source electroporation on the rat brain tissue. , 2014, Bioelectrochemistry.

[34]  G. V. van Dongen,et al.  Pharmacokinetics, Brain Delivery, and Efficacy in Brain Tumor-Bearing Mice of Glutathione Pegylated Liposomal Doxorubicin (2B3-101) , 2014, PloS one.

[35]  W. Pardridge,et al.  Drug Transport across the Blood–Brain Barrier , 2012, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[36]  Natalia Vykhodtseva,et al.  The kinetics of blood brain barrier permeability and targeted doxorubicin delivery into brain induced by focused ultrasound. , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[37]  Boris Rubinsky,et al.  MRI Study on Reversible and Irreversible Electroporation Induced Blood Brain Barrier Disruption , 2012, PloS one.

[38]  J. Simes,et al.  Phase 2 trial of temozolomide and pegylated liposomal doxorubicin in the treatment of patients with glioblastoma multiforme following concurrent radiotherapy and chemotherapy , 2010, Journal of clinical neuroscience.

[39]  S. Sourbron,et al.  A comparison of tracer kinetic models for T1‐weighted dynamic contrast‐enhanced MRI: Application in carcinoma of the cervix , 2010, Magnetic resonance in medicine.

[40]  J. Blakeley.  Drug delivery to brain tumors , 2008, Current neurology and neuroscience reports.

[41]  G. Broggi,et al.  Local drug delivery in recurrent malignant gliomas , 2005, Neurological Sciences.

[42]  T. Yamashima,et al.  In vivo and in vitro evidence for ATP-dependency of P-glycoprotein-mediated efflux of doxorubicin at the blood-brain barrier. , 1995, Biochemical pharmacology.

[43]  P. Tofts,et al.  Measurement of the blood‐brain barrier permeability and leakage space using dynamic MR imaging. 1. Fundamental concepts , 1991, Magnetic resonance in medicine.

[44]  V. P. Collins,et al.  Uptake of Adriamycin in tumour and surrounding brain tissue in patients with malignant gliomas , 1990, Acta Neurochirurgica.